
PetIQ PETQ
Annual report 2023
added 02-29-2024
PetIQ ROCE Ratio 2011-2026 | PETQ
Annual ROCE Ratio PetIQ
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.46 | -3.01 | 2.2 | -0.48 | 0.7 | 2.56 | 10.83 | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.83 | -3.01 | 2.61 |
Quarterly ROCE Ratio PetIQ
| 2023-Q3 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -9.67 | -3.49 | -3.93 | 1.92 | 2.59 | 2.77 | 2.27 | 2.22 | 0.56 | 0.13 | -1.98 | -2.21 | -1.27 | -0.52 | 0.46 | 2.79 | 3.36 | 1.8 | 2.96 | 2.8 | 6.18 | 10.83 | 10.97 | 6.91 | 1.47 | -2.44 | -2.61 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 10.97 | -9.67 | 1.29 |
ROCE Ratio of other stocks in the Drug manufacturers industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
-79.15 | - | 7.5 % | $ 6.35 M | ||
|
Alimera Sciences
ALIM
|
-4.18 | - | - | $ 142 M | ||
|
Aerie Pharmaceuticals
AERI
|
267.43 | - | - | $ 754 M | ||
|
Agile Therapeutics
AGRX
|
121.85 | - | 10.11 % | $ 58.2 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
3101.1 | - | 0.86 % | $ 117 M | ||
|
Canopy Growth Corporation
CGC
|
-24.04 | $ 0.97 | 2.36 % | $ 104 M | ||
|
Aurora Cannabis
ACB
|
-23.09 | $ 3.31 | 1.53 % | $ 86.3 M | ||
|
China Pharma Holdings
CPHI
|
-59.23 | $ 0.63 | 16.11 % | $ 11 M | ||
|
Catalent
CTLT
|
-20.78 | - | - | $ 11.5 B | ||
|
Athenex
ATNX
|
1076.15 | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
-57.41 | - | - | $ 2.06 B | ||
|
Cronos Group
CRON
|
-10.43 | $ 2.52 | 5.44 % | $ 1.31 B | ||
|
DURECT Corporation
DRRX
|
-249.5 | - | - | $ 50.1 M | ||
|
Emergent BioSolutions
EBS
|
-111.87 | $ 8.05 | -1.71 % | $ 412 M | ||
|
Endo International plc
ENDP
|
7.34 | - | - | $ 28.9 M | ||
|
Evoke Pharma
EVOK
|
-184.26 | - | - | $ 36.6 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
-39.6 | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
-85.61 | - | 2.45 % | $ 38.1 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
-8.06 | $ 3.05 | 7.77 % | $ 42.9 M | ||
|
Bausch Health Companies
BHC
|
-94.23 | $ 5.1 | 1.8 % | $ 1.86 B | ||
|
Harrow Health
HROW
|
58.18 | $ 34.0 | 2.16 % | $ 1.25 B | ||
|
Assertio Holdings
ASRT
|
-22.92 | $ 14.0 | 4.71 % | $ 89.6 M | ||
|
OptiNose
OPTN
|
26.27 | - | - | $ 1.08 B | ||
|
Evolus
EOLS
|
141.36 | $ 4.68 | 0.86 % | $ 302 M | ||
|
Eagle Pharmaceuticals
EGRX
|
34.66 | - | -39.89 % | $ 27.7 M | ||
|
Pacira BioSciences
PCRX
|
-9.43 | $ 22.65 | 2.44 % | $ 1.05 B | ||
|
OrganiGram Holdings
OGI
|
-35.84 | $ 1.36 | - | $ 402 M | ||
|
PLx Pharma
PLXP
|
-114.37 | - | -27.8 % | $ 2.56 M | ||
|
ProPhase Labs
PRPH
|
32.97 | - | - | $ 5.07 M | ||
|
Jupiter Wellness
JUPW
|
-116.71 | - | - | $ 33.6 M | ||
|
Radius Health
RDUS
|
21.53 | - | - | $ 1.42 B | ||
|
Relmada Therapeutics
RLMD
|
-68.31 | $ 5.86 | -3.46 % | $ 231 M | ||
|
Rockwell Medical
RMTI
|
-31.33 | $ 1.02 | -2.86 % | $ 23.8 M | ||
|
Lannett Company
LCI
|
70.21 | - | 1.15 % | $ 7.11 M | ||
|
Sundial Growers
SNDL
|
-68.48 | $ 1.36 | 0.74 % | $ 3.37 M | ||
|
SCYNEXIS
SCYX
|
-32.55 | $ 0.88 | -6.09 % | $ 43.9 M | ||
|
Solid Biosciences
SLDB
|
-90.02 | $ 7.14 | 1.56 % | $ 625 M | ||
|
Organogenesis Holdings
ORGO
|
-0.49 | $ 2.47 | 3.65 % | $ 325 M | ||
|
Neoleukin Therapeutics
NLTX
|
-29.88 | - | - | $ 193 M | ||
|
Perrigo Company plc
PRGO
|
-14.92 | $ 9.57 | 3.46 % | $ 1.33 B | ||
|
Sonoma Pharmaceuticals
SNOA
|
-84.11 | $ 2.55 | 4.94 % | $ 3.16 M | ||
|
Tilray
TLRY
|
-41.31 | $ 6.45 | 3.86 % | $ 3.99 B | ||
|
Recro Pharma
REPH
|
-6.09 | - | -4.76 % | $ 65.3 M | ||
|
TherapeuticsMD
TXMD
|
-29.1 | $ 2.31 | 3.12 % | $ 24.1 M | ||
|
Veru
VERU
|
-114.23 | $ 2.3 | 1.32 % | $ 310 M | ||
|
Viatris
VTRS
|
3.74 | $ 13.29 | 0.68 % | $ 16 B | ||
|
cbdMD
YCBD
|
-235.96 | $ 0.76 | 11.88 % | $ 3.28 M | ||
|
Tricida
TCDA
|
-70162.39 | - | - | $ 3.25 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
-76.25 | - | - | $ 55.5 M |